drugset / Trial / NCT00351325
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of multiple escalating doses of BMS-663513 when given in combination with paclitaxel and carboplatin.
Timeline
- Start
- 2007-09
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Urelumab | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | Urelumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Urelumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Urelumab | Monoclonal antibody | 10 mg/kg | — |